- PolyPeptide Group has installed pre-built modules at its Malmö, Sweden, facility as part of a €100 million expansion project to double solid-phase peptide synthesis (SPPS) capacity.
- The modular approach, largely funded by a major pharmaceutical partner, is expected to accelerate timelines and create around 100 new jobs.
PolyPeptide Group AG has reached a key milestone in its Malmö, Sweden expansion by completing the delivery and installation of pre-built modules at the site. The development is part of a modular construction project announced in January 2025, which aims to double the company’s solid-phase peptide synthesis (SPPS) capacity.
The investment of approximately €100 million, supported largely by a large pharmaceutical partner, forms a central element of the company’s mid-term strategy to meet rising global demand for peptides. Following installation, the modules will undergo mechanical completion, automation, qualification, and commissioning.
“The Malmö expansion is a cornerstone of our mid-term growth strategy. By leveraging modular construction and advanced automation, we’re accelerating capacity expansion to meet rising demand from key customers.” He added that the investment also supports the company’s ambition to double 2023 revenue by 2028.
CEO Juan José González
The expansion will create around 100 new permanent positions while ensuring continuity of existing manufacturing operations. The company highlighted the use of proprietary systems, advanced automation, and stringent GMP standards to maintain quality.
PolyPeptide confirmed that the additional capacity will support one of its large commercial agreements and contribute to long-term growth initiatives. The company expects to continue allocating 15–20% of revenue to capital expenditures on average to secure capacity beyond 2028.
